208 related articles for article (PubMed ID: 31646741)
1. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract][Full Text] [Related]
2. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
3. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
4. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
Kopecky J; Kubecek O; Priester P; Vosmikova H; Cermakova E; Kyllarova A
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):393-404. PubMed ID: 34446937
[TBL] [Abstract][Full Text] [Related]
6. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
7. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study).
Namikawa K; Ito T; Yoshikawa S; Yoshino K; Kiniwa Y; Ohe S; Isei T; Takenouchi T; Kato H; Mizuhashi S; Fukushima S; Yamamoto Y; Inozume T; Fujisawa Y; Yamasaki O; Nakamura Y; Asai J; Maekawa T; Funakoshi T; Matsushita S; Nakano E; Oashi K; Kato J; Uhara H; Miyagawa T; Uchi H; Hatta N; Tsutsui K; Maeda T; Matsuya T; Yanagisawa H; Muto I; Okumura M; Ogata D; Yamazaki N
Cancer Med; 2023 Sep; 12(17):17967-17980. PubMed ID: 37584204
[TBL] [Abstract][Full Text] [Related]
9. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
10. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
11. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
12. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600
Klein S; Mauch C; Brinker K; Noh KW; Knez S; Büttner R; Quaas A; Helbig D
Sci Rep; 2021 Jan; 11(1):1834. PubMed ID: 33469107
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and overall survival in
Atkins MB; Julian C; Secrest MH; Lee J; Abajo-Guijarro AM; McKenna E
Future Oncol; 2022 Jun; 18(18):2233-2245. PubMed ID: 35441522
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract][Full Text] [Related]
16. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
Johnson DB; Pectasides E; Feld E; Ye F; Zhao S; Johnpulle R; Merritt R; McDermott DF; Puzanov I; Lawrence D; Sosman JA; Buchbinder E; Sullivan RJ
J Immunother; 2017 Jan; 40(1):31-35. PubMed ID: 27846054
[TBL] [Abstract][Full Text] [Related]
17. Treatment management for
Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG.
Zaremba A; Mohr P; Gutzmer R; Meier F; Pföhler C; Weichenthal M; Terheyden P; Forschner A; Leiter U; Ulrich J; Utikal J; Welzel J; Kaatz M; Gebhardt C; Herbst R; Sindrilaru A; Dippel E; Sachse M; Meiss F; Heinzerling L; Haferkamp S; Weishaupt C; Löffler H; Kreft S; Griewank K; Livingstone E; Schadendorf D; Ugurel S; Zimmer L
Eur J Cancer; 2023 Jul; 188():140-151. PubMed ID: 37245442
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
20. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
